Testing SGLT2 pill and potassium nitrate for heart failure with preserved EF
Part of Heart & circulation clinical trials.
This trial studies whether two medicines—an SGLT2 inhibitor and potassium nitrate—can improve symptoms and heart function in people with heart failure with preserved ejection fraction (HFpEF). It focuses on people who still have signs of “stiff” or high filling pressure in the heart despite a normal-ish ejection fraction.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older
- You have heart failure symptoms that are moderate, like NYHA Class II to III
- Your echocardiogram or MRI shows left ventricular ejection fraction is 50% or higher
- Your heart tests suggest higher filling pressures (they look for specific echocardiogram patterns, past pressure measurements, or a prior hospitalization needing IV diuretics)
- You’re medically stable and able to do exercise testing
- You do not have several key conditions that could make the study unsafe, including pregnancy, certain valve diseases, serious lung disease, very low kidney function, and poorly controlled heart rhythm or blood pressure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how matching heart “filling pressure” and heart muscle “energy use” may improve understanding or treatment of HFpEF, a type of heart failure with preserved pumping strength. You may be asked to have heart scans/tests and follow a study plan if your symptoms and test results fit.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This early-phase trial tests a treatment that aims to improve the “natriuretic peptide” hormone system in people with HFpEF (heart failure with preserved pumping strength). It may help reduce symptoms and improve heart and fluid pressure behavior, especially in certain related conditions like kidney disease.
This study tests an investigational medicine called EDG-15400 for people with a type of heart failure where the heart muscle is stiff and doesn't relax properly, even though the pumping function is normal. The goal is to see if the medicine improves symptoms and daily functioning.
This trial tests if a medicine (SGLT2 inhibitor) given to people with high blood pressure and early signs of heart stress can help prevent heart failure. You may join if your blood pressure is controlled but tests show your heart is beginning to struggle.
This Phase 3 trial tests whether starting an SGLT2 inhibitor early in the hospital can improve outcomes for people at high risk after acute (sudden) heart failure. If you qualify, you would be randomized to receive the study medicine or standard care, started within 12 hours of admission.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.